Rapid depletion of “catch-and-release” anti-ASGR1 antibody in vivo

References

• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–16. doi:10.1038/256495a0.
   PubMed Web of Science ®Google Scholar
• Carter PJ, Rajpal A. Designing antibodies as therapeutics. Cell. 2022;185(15):2789–805. doi:10.1016/j.cell.2022.05.029.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, Reichert JM. Antibodies to watch in 2023. MAbs. 2023;15(1):2153410. doi:10.1080/19420862.2022.2153410.
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715–25. doi:10.1038/nri2155.
   PubMed Web of Science ®Google Scholar
• Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacom & Syst Pharma. 2017;6(9):576–88. doi:10.1002/psp4.12224.
   PubMedGoogle Scholar
• Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 2018;9(1):15–32. doi:10.1007/s13238-017-0408-4.
   PubMed Web of Science ®Google Scholar
• Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol. 2008;317:103–23.
   PubMed Web of Science ®Google Scholar
• Heo YA. Satralizumab: first approval. Drugs. 2020;80(14):1477–82. doi:10.1007/s40265-020-01380-2.
   PubMed Web of Science ®Google Scholar
• Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11(1–2):81–88. doi:10.1016/S1359-6446(05)03638-X.
   PubMed Web of Science ®Google Scholar
• Ward ES, Ober RJ. Targeting FcRn to generate antibody-based therapeutics. Trends Pharmacol Sci. 2018;39(10):892–904. doi:10.1016/j.tips.2018.07.007.
   PubMed Web of Science ®Google Scholar
• Ward ES, Devanaboyina SC, Ober RJ. Targeting FcRn for the modulation of antibody dynamics. Mol Immunol. 2015;67(2):131–41. doi:10.1016/j.molimm.2015.02.007.
   PubMed Web of Science ®Google Scholar
• Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, Ober RJ, Ward ES. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol. 1997;15(7):637–40. doi:10.1038/nbt0797-637.
   PubMed Web of Science ®Google Scholar
• Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IWL, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010;28(2):157–59. doi:10.1038/nbt.1601.
   PubMed Web of Science ®Google Scholar
• Borrok MJ, Wu Y, Beyaz N, Yu X-Q, Oganesyan V, Dall’Acqua WF, Tsui P. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. J Biol Chem. 2015;290(7):4282–90. doi:10.1074/jbc.M114.603712.
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Criste R, Dall’Acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP. A novel investigational fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013;57(12):6147–53. doi:10.1128/AAC.01285-13.
   PubMed Web of Science ®Google Scholar
• Conner KP, Devanaboyina SC, Thomas VA, Rock DA. The biodistribution of therapeutic proteins: mechanism, implications for pharmacokinetics, and methods of evaluation. Pharmacol Ther. 2020;212:107574. doi:10.1016/j.pharmthera.2020.107574.
   PubMed Web of Science ®Google Scholar
• Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, Moriyama C, Watanabe T, Takubo R, Doi Y, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol. 2010;28(11):1203–07. doi:10.1038/nbt.1691.
   PubMed Web of Science ®Google Scholar
• Devanaboyina SC, Lynch SM, Ober RJ, Ram S, Kim D, Puig-Canto A, Breen S, Kasturirangan S, Fowler S, Peng L, et al. The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics. MAbs. 2013;5(6):851–59. doi:10.4161/mabs.26389.
   PubMed Web of Science ®Google Scholar
• Hironiwa N, Ishii S, Kadono S, Iwayanagi Y, Mimoto F, Habu K, Igawa T, Hattori K. Calcium-dependent antigen binding as a novel modality for antibody recycling by endosomal antigen dissociation. MAbs. 2016;8(1):65–73. doi:10.1080/19420862.2015.1110660.
   PubMed Web of Science ®Google Scholar
• Yang D, Giragossian C, Castellano S, Lasaro M, Xiao H, Saraf H, Hess Kenny C, Rybina I, Huang Z-F, Ahlberg J, et al. Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn. MAbs. 2017;9(7):1105–17. doi:10.1080/19420862.2017.1359455.
   PubMed Web of Science ®Google Scholar
• Engler FA, Polli JR, Li T, An B, Otteneder M, Qu J, Balthasar JP. “Catch-and-release” anti-carcinoembryonic antigen monoclonal antibody leads to greater plasma and tumor exposure in a mouse model of colorectal cancer. J Pharmacol Exp Ther. 2018;366(1):205–19. doi:10.1124/jpet.117.246900.
   PubMed Web of Science ®Google Scholar
• Braun JR, Willnow TE, Ishibashi S, Ashwell G, Herz J. The major subunit of the asialoglycoprotein receptor is expressed on the hepatocellular surface in mice lacking the minor receptor subunit. J Biol Chem. 1996;271(35):21160–66. doi:10.1074/jbc.271.35.21160.
   PubMed Web of Science ®Google Scholar
• Ashwell G, Morell AG. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol. 1974;41:99–128.
   PubMedGoogle Scholar
• Li Y, Huang G, Diakur J, Wiebe LI. Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development. Curr Drug Deliv. 2008;5(4):299–302. doi:10.2174/156720108785915069.
   PubMedGoogle Scholar
• D’Souza AA, Devarajan PV. Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications. J Control Release. 2015;203:126–39. doi:10.1016/j.jconrel.2015.02.022.
   PubMed Web of Science ®Google Scholar
• Nioi P, Sigurdsson A, Thorleifsson G, Helgason H, Agustsdottir AB, Norddahl GL, Helgadottir A, Magnusdottir A, Jonasdottir A, Gretarsdottir S, et al. Variant ASGR1 associated with a reduced risk of coronary artery disease. N Engl J Med. 2016;374(22):2131–41. doi:10.1056/NEJMoa1508419.
   PubMed Web of Science ®Google Scholar
• Schwartz AL, Fridovich SE, Knowles BB, Lodish HF. Characterization of the asialoglycoprotein receptor in a continuous hepatoma line. J Biol Chem. 1981;256(17):8878–81. doi:10.1016/S0021-9258(19)52477-2.
   PubMed Web of Science ®Google Scholar
• Bon C, Hofer T, Bousquet-Melou A, Davies MR, Krippendorff BF. Capacity limits of asialoglycoprotein receptor-mediated liver targeting. MAbs. 2017;9(8):1360–69. doi:10.1080/19420862.2017.1373924.
   PubMed Web of Science ®Google Scholar
• Dall’acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S. Increasing the affinity of a human IgG1 for the neonatal fc receptor: biological consequences. J Immunol. 2002;169(9):5171–80. doi:10.4049/jimmunol.169.9.5171.
   PubMed Web of Science ®Google Scholar
• Kim JK, Firan M, Radu CG, Kim C-H, Ghetie V, Ward ES. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol. 1999;29(9):2819–25. doi:10.1002/(SICI)1521-4141(199909)29:09<2819:AID-IMMU2819>3.0.CO;2-6.
   PubMed Web of Science ®Google Scholar
• Jacobsen FW, Stevenson R, Li C, Salimi-Moosavi H, Liu L, Wen J, Luo Q, Daris K, Buck L, Miller S, et al. Engineering an IgG scaffold lacking effector function with optimized developability. J Biol Chem. 2017;292(5):1865–75. doi:10.1074/jbc.M116.748525.
   PubMed Web of Science ®Google Scholar
• Liu L, Jacobsen FW, Everds N, Zhuang Y, Yu YB, Li N, Clark D, Nguyen MP, Fort M, Narayanan P, et al. Biological characterization of a stable effector functionless (SEFL) monoclonal antibody scaffold in vitro. J Biol Chem. 2017;292(5):1876–83. doi:10.1074/jbc.M116.748707.
   PubMed Web of Science ®Google Scholar
• Avery LB, Wang M, Kavosi MS, Joyce A, Kurz JC, Fan Y-Y, Dowty ME, Zhang M, Zhang Y, Cheng A, et al. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs. 2016;8(6):1064–78. doi:10.1080/19420862.2016.1193660.
   PubMed Web of Science ®Google Scholar
• Peletier LA, Gabrielsson J. Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification. J Pharmacokinet Pharmacodyn. 2012;39(5):429–51. doi:10.1007/s10928-012-9260-6.
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog. 2008;21(1):11–16. doi:10.1021/bp040016j.
   Google Scholar
• Liu L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci. 2015;104(6):1866–84. doi:10.1002/jps.24444.
   PubMed Web of Science ®Google Scholar
• Onizuka T, Shimizu H, Moriwaki Y, Nakano T, Kanai S, Shimada I, Takahashi H. NMR study of ligand release from asialoglycoprotein receptor under solution conditions in early endosomes. The FEBS J. 2012;279(15):2645–56. doi:10.1111/j.1742-4658.2012.08643.x.
   PubMed Web of Science ®Google Scholar
• Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol. 2005;23(10):1283–88. doi:10.1038/nbt1143.
   PubMed Web of Science ®Google Scholar
• Andersen JT, Dalhus B, Viuff D, Ravn BT, Gunnarsen KS, Plumridge A, Bunting K, Antunes F, Williamson R, Athwal S, et al. Extending serum half-life of albumin by engineering neonatal fc receptor (FcRn) binding. J Biol Chem. 2014;289(19):13492–502. doi:10.1074/jbc.M114.549832.
   PubMed Web of Science ®Google Scholar
• Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol. 2009;68(1):61–76. doi:10.1111/j.1365-2125.2009.03401.x.
   PubMed Web of Science ®Google Scholar
• Chaparro-Riggers J, Liang H, DeVay RM, Bai L, Sutton JE, Chen W, Geng T, Lindquist K, Casas MG, Boustany LM, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem. 2012;287(14):11090–97. doi:10.1074/jbc.M111.319764.
   PubMed Web of Science ®Google Scholar
• Bonvin P, Venet S, Fontaine G, Ravn U, Gueneau F, Kosco-Vilbois M, Proudfoot AE, Fischer N. De novo isolation of antibodies with pH-dependent binding properties. MAbs. 2015;7(2):294–302. doi:10.1080/19420862.2015.1006993.
   PubMed Web of Science ®Google Scholar
• Meier M, Bider MD, Malashkevich VN, Spiess M, Burkhard P. Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor. J Mol Biol. 2000;300(4):857–65. doi:10.1006/jmbi.2000.3853.
   PubMed Web of Science ®Google Scholar
• Hoober JK. ASGR1 and Its enigmatic relative, CLEC10A. Int J Mol Sci. 2020;21(14):4818. doi:10.3390/ijms21144818.
   PubMed Web of Science ®Google Scholar
• Igawa T, Maeda A, Haraya K, Tachibana T, Iwayanagi Y, Mimoto F, Higuchi Y, Ishii S, Tamba S, Hironiwa N, et al. Engineered monoclonal antibody with novel antigen-sweeping activity in vivo. PLOS ONE. 2013;8(5):e63236. doi:10.1371/journal.pone.0063236.
   PubMed Web of Science ®Google Scholar
• Miki K, Kubota K, Inoue Y, Vera DR, Makuuchi M. Receptor measurements via Tc-GSA kinetic modeling are proportional to functional hepatocellular mass. Gastroenterol. 2001;120(5):733–37. doi:10.1016/S0016-5085(08)82723-0.
   Web of Science ®Google Scholar
• Shi B, Abrams M, Sepp-Lorenzino L. Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma. J Histochem Cytochem. 2013;61(12):901–09. doi:10.1369/0022155413503662.
   PubMed Web of Science ®Google Scholar
• Ober RJ, Martinez C, Vaccaro C, Zhou J, Ward ES. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol. 2004;172(4):2021–29. doi:10.4049/jimmunol.172.4.2021.
   PubMed Web of Science ®Google Scholar
• Pyzik M, Rath T, Kuo TT, Win S, Baker K, Hubbard JJ, Grenha R, Gandhi A, Krämer TD, Mezo AR, et al. Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury. Proc Natl Acad Sci USA. 2017;114(14):E2862–71. doi:10.1073/pnas.1618291114.
   PubMed Web of Science ®Google Scholar
• Kang JC, Sun W, Khare P, Karimi M, Wang X, Shen Y, Ober RJ, Ward ES. Engineering a HER2-specific antibody–drug conjugate to increase lysosomal delivery and therapeutic efficacy. Nat Biotechnol. 2019;37(5):523–26. doi:10.1038/s41587-019-0073-7.
   PubMed Web of Science ®Google Scholar
• Polli JR, Balthasar JP. Cell penetrating peptides conjugated to Anti-Carcinoembryonic Antigen “catch-and-release” monoclonal antibodies alter plasma and tissue pharmacokinetics in colorectal cancer xenograft mice. Bioconjug Chem. 2022;33(8):1456–66. doi:10.1021/acs.bioconjchem.2c00152.
   PubMed Web of Science ®Google Scholar
• Ahn G, Banik SM, Bertozzi CR. Degradation from the outside in: targeting extracellular and membrane proteins for degradation through the endolysosomal pathway. Cell Chem Biol. 2021;28(7):1072–80. doi:10.1016/j.chembiol.2021.02.024.
   PubMed Web of Science ®Google Scholar
• Engler C, Kandzia R, Marillonnet S, El-Shemy HA. A one pot, one step, precision cloning method with high throughput capability. PLOS ONE. 2008;3(11):e3647. doi:10.1371/journal.pone.0003647.
   PubMed Web of Science ®Google Scholar
• Li D, Partin AC, Zhao L, Chen I, Michaels ML, Wang Z, Garces F, Gong D, Riley TP. Protocol for high-throughput cloning, expression, purification, and evaluation of bispecific antibodies. Star Protoc. 2022;3(2):101428. doi:10.1016/j.xpro.2022.101428.
   PubMedGoogle Scholar
• Qiao SW, Kobayashi K, Johansen F-E, Sollid LM, Andersen JT, Milford E, Roopenian DC, Lencer WI, Blumberg RS. Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci USA. 2008;105(27):9337–42. doi:10.1073/pnas.0801717105.
   PubMed Web of Science ®Google Scholar
• Liebler DC, Zimmerman LJ. Targeted quantitation of proteins by mass spectrometry. Biochem. 2013;52(22):3797–806. doi:10.1021/bi400110b.
   PubMed Web of Science ®Google Scholar
• Pino LK, Searle BC, Bollinger JG, Nunn B, MacLean B, MacCoss MJ. The skyline ecosystem: informatics for quantitative mass spectrometry proteomics. Mass Spectrom Rev. 2020;39(3):229–44. doi:10.1002/mas.21540.
   PubMed Web of Science ®Google Scholar
• Charni-Natan M, Goldstein I. Protocol for primary mouse hepatocyte isolation. Star Protoc. 2020;1(2):100086. doi:10.1016/j.xpro.2020.100086.
   PubMedGoogle Scholar